Literature DB >> 34173094

The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.

O G Artamonova1, A E Karamova2, A A Nikonorov2, D A Verbenko2, E L Vasileva2, A A Kubanov2.   

Abstract

In patients with moderate-to-severe and severe psoriasis and high efficacy of therapy (PASI≥75) with signaling pathway inhibitors (apremilast, tofacitinib), cytokine spectra in the skin and blood plasma were studied using xMAP technology at baseline and on weeks 14 and 26 of treatment. Comparison of cytokine levels in psoriatic lesional skin and plasma samples of patients treated with apremilast or tofacitinib revealed statistical difference only for IFNγ level (р<0.05) at week 26.

Entities:  

Keywords:  Janus kinase inhibitors; apremilast; phosphodiesterase-4 inhibitor; psoriasis; tofacitinib

Mesh：

Substances：

Year:  2021        PMID： 34173094     DOI： 10.1007/s10517-021-05196-2

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  10 in total

1.  Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.

Authors:  Sandra Garcet; Kristine Nograles; Joel Correa da Rosa; Peter H Schafer; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2018-06-21       Impact factor: 10.793

Review 2.  Apremilast: A Review in Psoriasis and Psoriatic Arthritis.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

3.  Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.

Authors:  K A Papp; M A Menter; M Abe; B Elewski; S R Feldman; A B Gottlieb; R Langley; T Luger; D Thaci; M Buonanno; P Gupta; J Proulx; S Lan; R Wolk
Journal:  Br J Dermatol       Date:  2015-10       Impact factor: 9.302

Review 4.  The role of JAK/STAT signaling pathway and its inhibitors in diseases.

Authors:  Ping Xin; Xiaoyun Xu; Chengjie Deng; Shuang Liu; Youzhi Wang; Xuegang Zhou; Hongxing Ma; Donghua Wei; Shiqin Sun
Journal:  Int Immunopharmacol       Date:  2020-01-20       Impact factor: 4.932

5.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

Authors:  Kim Papp; Kristian Reich; Craig L Leonardi; Leon Kircik; Sergio Chimenti; Richard G B Langley; ChiaChi Hu; Randall M Stevens; Robert M Day; Kenneth B Gordon; Neil J Korman; Christopher E M Griffiths
Journal:  J Am Acad Dermatol       Date:  2015-07       Impact factor: 11.527

6.  Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors.

Authors:  Camila Cataldi; Naiara Lourenço Mari; Marcell Alysson Batisti Lozovoy; Ligia Márcia Mário Martins; Edna Maria Vissoci Reiche; Michael Maes; Isaias Dichi; Andréa Name Colado Simão
Journal:  Inflamm Res       Date:  2019-05-06       Impact factor: 4.575

Review 7.  Regulation of cytokine signaling and inflammation.

Authors:  Toshitkatsu Hanada; Akihiko Yoshimura
Journal:  Cytokine Growth Factor Rev       Date:  2002 Aug-Oct       Impact factor: 7.638

8.  Simultaneous detection and quantification of six equine cytokines in plasma using a fluorescent microsphere immunoassay (FMIA).

Authors:  Sarah A Hall; Diana Stucke; Beatrice Morrone; Dirk Lebelt; Adroaldo J Zanella
Journal:  MethodsX       Date:  2015-04-25

9.  Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis.

Authors:  Young Ji Hwang; Ho Jung Jung; Min Jung Kim; Nam Kyung Roh; Jae Wook Jung; Yang Won Lee; Yong Beom Choe; Kyu Joong Ahn
Journal:  Mediators Inflamm       Date:  2014-08-14       Impact factor: 4.711

Review 10.  Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.

Authors:  Heng Li; Jianping Zuo; Wei Tang
Journal:  Front Pharmacol       Date:  2018-10-17       Impact factor: 5.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.